^[1] Song Xet al. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. Am J Health Syst Pharm 2012; 69: 329–338

^[2] Lopes et al. Apixaban for Reduction in Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal 2010; 159: 331–9